{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:20:34Z","timestamp":1791181234921,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jaut.2013.12.002","type":"journal-article","created":{"date-parts":[[2013,12,21]],"date-time":"2013-12-21T20:15:21Z","timestamp":1387656921000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment"],"prefix":"10.1016","volume":"50","author":[{"given":"G.","family":"Cambridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Serre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Leandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.W.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2013.12.002_bib1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.berh.2006.05.010","article-title":"B\u00a0cell depletion therapy in rheumatic disease","volume":"20","author":"Edwards","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.002_bib2","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1002\/art.30567","article-title":"Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system","volume":"63","author":"Boumans","year":"2011","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib4","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment","volume":"58","author":"Roll","year":"2008","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.002_bib6","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1002\/art.30596","article-title":"Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment","volume":"63","author":"Lal","year":"2011","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib7","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaut.2013.12.002_bib9","first-page":"20","article-title":"Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial","volume":"35","author":"Mease","year":"2008","journal-title":"J\u00a0Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002432","article-title":"A\u00a0plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis","volume":"3","author":"Owczarczyk","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaut.2013.12.002_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"Dorner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaut.2013.12.002_bib12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment","volume":"62","author":"Vital","year":"2010","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib13","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib14","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1002\/art.27702","article-title":"Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients","volume":"62","author":"Thurlings","year":"2010","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4049\/jimmunol.181.1.785","article-title":"B\u00a0lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis","volume":"181","author":"Cantaert","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2008.092791","article-title":"Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation","volume":"68","author":"Teng","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib18","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1136\/ard.2010.131326","article-title":"B-cell-activating factor receptor expression on naive and memory B cells: relationship with relapse in patients with rheumatoid arthritis following B-cell depletion therapy","volume":"69","author":"de la Torre","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib19","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.4049\/jimmunol.0803660","article-title":"TLR4-mediated signaling induces MMP9-dependent cleavage of B cell surface CD23","volume":"183","author":"Jackson","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/ar2773","article-title":"Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort","volume":"11","author":"Gottenberg","year":"2009","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.jaut.2013.12.002_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B\u00a0cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib22","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1136\/ard.2009.126441","article-title":"Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity","volume":"69","author":"Kormelink","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib24","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1136\/ard.2010.142299","article-title":"Diagnostic performance of the ACR\/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)","volume":"70","author":"Alves","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib25","first-page":"S93","article-title":"The disease activity score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jbspin.2004.07.004","article-title":"Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis","volume":"71","author":"Sebbag","year":"2004","journal-title":"Jt Bone Spine: revue du rhumatisme"},{"key":"10.1016\/j.jaut.2013.12.002_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/cei.12114","article-title":"The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses","volume":"173","author":"Modi","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.25036","article-title":"Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients","volume":"62","author":"Snir","year":"2010","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib29","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar2497","article-title":"Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab","volume":"10","author":"Rosengren","year":"2008","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.jaut.2013.12.002_bib30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.23284","article-title":"Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen","volume":"58","author":"Clavel","year":"2008","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib31","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10067-010-1674-1","article-title":"Normalization of serum-free light chains in patients with systemic lupus erythematosus upon rituximab treatment and correlation with biological disease activity","volume":"30","author":"Chiche","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaut.2013.12.002_bib32","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/art.1780370614","article-title":"Preferential utilization of a novel V lambda 3 gene in monoclonal rheumatoid factors derived from the synovial cells of rheumatoid arthritis patients","volume":"37","author":"Ermel","year":"1994","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1046\/j.1365-2249.1999.00767.x","article-title":"Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL\/lambda genes","volume":"115","author":"Krenn","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib34","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/rheumatology\/kep314","article-title":"Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis","volume":"48","author":"Quartuccio","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.002_bib35","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1084\/jem.173.2.487","article-title":"Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells","volume":"173","author":"Roosnek","year":"1991","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2013.12.002_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/rheumatology\/37.2.126","article-title":"Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen","volume":"37","author":"Edwards","year":"1998","journal-title":"Br J Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib37","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.167.7.3610","article-title":"Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome","volume":"167","author":"Bohnhorst","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/003655498750003500","article-title":"Serum sCD23 in patients with lepromatous and tuberculoid leprosy","volume":"30","author":"Bansal","year":"1998","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/eji.1830180118","article-title":"Human recombinant interleukin 4 induces normal B cells to produce soluble CD23\/IgE-binding factor analogous to that spontaneously released by lymphoblastoid B cell lines","volume":"18","author":"Bonnefoy","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib40","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20042321","article-title":"Impaired early B cell tolerance in patients with rheumatoid arthritis","volume":"201","author":"Samuels","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jaut.2013.12.002_bib41","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","article-title":"Human blood IgM \u201cmemory\u201d B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire","volume":"104","author":"Weller","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2013.12.002_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1046\/j.1365-2249.1997.4061306.x","article-title":"Expression of molecules involved in B lymphocyte survival and differentiation by synovial fibroblasts","volume":"108","author":"Edwards","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib43","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1136\/ard.2011.150219","article-title":"A\u00a0BAFF\/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells","volume":"70","author":"Bombardieri","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in autoimmunity","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J\u00a0Clin Investig"},{"key":"10.1016\/j.jaut.2013.12.002_bib46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/ni.1666","article-title":"Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling","volume":"9","author":"Stadanlick","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib47","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/art.21489","article-title":"Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus","volume":"52","author":"Carter","year":"2005","journal-title":"Arthr Rheum"},{"key":"10.1016\/j.jaut.2013.12.002_bib48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaut.2013.12.002_bib49","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.4049\/jimmunol.178.9.5612","article-title":"Divergent effects of BAFF on human memory B cell differentiation into Ig-secreting cells","volume":"178","author":"Darce","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaut.2013.12.002_bib50","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaut.2013.12.002_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.1102321","article-title":"Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors","volume":"188","author":"Kreuzaler","year":"2012","journal-title":"J\u00a0Immunol"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841113001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:09:52Z","timestamp":1760256592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841113001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":51,"alternative-id":["S0896841113001492"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.002","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2013.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}